Almac expands U.K. capacity with the acquisition of blistering tech

Wednesday, October 3, 2012 03:24 PM

Almac, a global service provider, has expanded its MHRA/FDA approved U.K. commercial packaging facility with the acquisition of a state-of-the-art Noack N 623 blister packaging line from Romaco.

The acquisition comes in response to growing client demand for enhanced flexibility related to larger blister sizes and innovative multi-unit blister formats, coupled to a requirement for non-permeability and enhanced environmental protection, particularly product humidity control.

This highly flexible, cGMP compliant technology can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm. With its automatic feeding system, filling inspection and ejection station and shorter set-up times, the line provides increased productivity, processing over 25,000 blisters per hour, including multi-product blisters.

“Blister size and dosage formats are becoming increasingly more complex. Additionally, product handling for innovative new molecules often requires enhanced environmental controls. This investment allows Almac, through its pharma services business unit, to offer this additional flexibility,” said Geoff Sloan, vice president of manufacturing operations, Almac. “Through this acquisition, coupled with our immanent entry into the U.S. commercial packaging market, we continue to expand our capabilities and flexibility to meet our client’s needs.”

Bernd Webel, sales director of Romaco, added, “The blister technology from Romaco Noack offers high OEE values and low lifecycle costs. Product changeovers are carried out easily and cleaning is quickly done. Our machines prove themselves flexible in operation and versatile in use.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs